Skip to main content
Equibles
LIVN logo

LIVN · LivaNova PLC · Metrics

Track LIVN — free

Use LIVN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LIVN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$80.38 -0.24 (-0.30%) Q2 2026 earnings call transcript
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.44B
Shares
55.09M
Volume · Oct 27 383.61K Avg daily vol (3M) 645.32K

LIVN metrics

107 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$80.38
Market cap
$4.44B

Price action

20 metrics
Price change (1W)
+3.2%
Price change (30D)
+4.4%
Price change (3M)
+0.0%
Price change (6M)
+27.1%
Price change (YTD)
+31.0%
Price change (1Y)
+46.9%
Trailing year
Price change (5Y)
+0.2%
52-week high
$85.33
52-week low
$49.57
Change from 52-week high
-5.5%
Change from 52-week low
+62.6%
Annualized volatility
36.2%
Annualized volatility (3M)
31.0%
Beta
1.0
RSI (14D)
59.0
Price vs SMA 50
+2.7%
Price vs SMA 200
+11.1%
Avg volume (3M)
646,906
Relative volume
0.6
Average dollar volume
$51.01M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
55.09M

Valuation

12 metrics
P / E (TTM)
23.8
Trailing earnings · reciprocal yield 4.2%
PEG ratio
0.1
EV / revenue
2.9×
reciprocal yield 34.8%
EV / EBITDA
38.9×
reciprocal yield 2.6%
EV / EBIT
22.6×
reciprocal yield 4.4%
P / sales
3.0×
reciprocal yield 33.0%
P / book
3.4
reciprocal yield 29.7%
FCF yield
3.3%
TTM · current market cap
Buyback yield
1.2%
P / FCF
30.1
reciprocal yield 3.3%
P / operating cash flow
17.9
reciprocal yield 5.6%
Earnings yield
4.2%

Historical valuation

8 metrics
P / E historical average (3Y)
203.5×
reciprocal yield 0.5%
P / E historical average (5Y)
203.5×
reciprocal yield 0.5%
EV / revenue historical average (3Y)
2.4×
reciprocal yield 41.6%
EV / revenue historical average (5Y)
2.9×
reciprocal yield 35.0%
EV / EBIT historical average (3Y)
108.0×
reciprocal yield 0.9%
EV / EBIT historical average (5Y)
119.7×
reciprocal yield 0.8%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
68.1%
Operating margin
12.7%
Trailing 12 months
Net margin
12.8%
Gross profit (TTM)
$1.00B
Operating profit (TTM)
$187.54M
Net income (TTM)
$188.55M
Trailing 12 months
Diluted EPS (TTM)
$3.39
FCF margin
10.1%
Effective tax rate
-76.3%

Per share

11 metrics
Revenue per diluted share (TTM)
$26.60
Gross profit per diluted share (TTM)
$18.11
Operating profit per diluted share (TTM)
$3.39
EBITDA per diluted share (TTM)
$2.38
Net income per diluted share (TTM)
$3.39
Operating cash flow per diluted share (TTM)
$4.53
Free cash flow per diluted share (TTM)
$2.70
Capital expenditures per diluted share (TTM)
$1.83
R&D per diluted share (TTM)
$3.85
Stock compensation per diluted share (TTM)
$0.80
Book value per share
$21.96

Growth

11 metrics
Revenue growth YoY
+10.8%
Year over year
Net income growth YoY
+299.7%
Revenue (TTM)
$1.47B
Trailing 12 months
EPS growth YoY
+286.0%
Shares change YoY
+2.9%
Year over year · more shares
Revenue CAGR (3Y)
+10.8%
Revenue CAGR (5Y)
+8.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+58.6%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
14.2%
Return on assets
7.1%
Debt / equity
0.2
Current ratio
1.4
EBITDA (TTM)
$116.81M
Free cash flow (TTM)
$148.31M
Quick ratio
1.2
Interest coverage
5.4
Net debt / EBITDA
0.7
Return on invested capital
—
Trailing 12 months
Net cash
$223.13M
Latest balance sheet
Cash & equivalents
$516.62M
Total assets
$2.64B
Total debt
$293.49M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$249.26M
Capital expenditures (TTM)
$100.95M
R&D (TTM)
$213.06M
SG&A (TTM)
$583.58M
Stock compensation (TTM)
$44.49M
R&D / revenue
14.5%
Stock compensation / revenue
3.0%

Ownership (13F)

9 metrics
13F filers
306
13F filer change QoQ
+14
Institutional ownership
107.8%
Conviction holders (share of 13F filers)
1.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+1.0%
Holder tenure
15.3
Price vs estimated holder cost
+39.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.9%

Short interest

3 metrics
Short interest
11.3%
Latest settlement · 10.6 days to cover
Days to cover
10.6d
Short-squeeze score
83 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$799,783
Insider-sentiment score
28 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1639691 CUSIP G5509L101 13F (30d) 53 filings 52 filers Visit website Investor relations